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Introduction {#sec005}
============

Tuberculosis (TB) continues to be an epidemic in Sub-Saharan Africa and the leading infectious cause of death globally. Mozambique is one of the 30 high burden tuberculosis countries. The World Health Organization (WHO) estimates its TB incidence rate at 551/100,000 in 2018 translating to an estimate of 162,000 new individuals each year. \[[@pone.0236262.ref001]\] WHO estimates are based on its assessment of data notification quality and coverage, prevalence of the disease and information on death registration. In Mozambique 92,381 people were diagnosed and notified with TB in 2018, resulting in a treatment coverage rate of only 57%. Coverage for multi-drug resistant or rifampin resistant TB (MDR/RR-TB) was even lower, 14% (1,134 people notified with RR/MDR-TB of the estimated 8,300 total). \[[@pone.0236262.ref001]\] TB continues to be a leading cause of death in Mozambique, and the primary cause of death and disability among people living with HIV. \[[@pone.0236262.ref002]--[@pone.0236262.ref004]\] The high incidence rate was fueled by the HIV epidemic with a national prevalence of 13.2% and compounded by poverty. The estimated average gross national income per capita is only \$440 USD, one of the lowest in Africa. \[[@pone.0236262.ref005]--[@pone.0236262.ref007]\]

TB case detection, diagnosis and notification is primarily conducted in health centers using passive case finding (waiting for the individual to present with TB-related symptoms) and testing with smear microscopy (SS) or increasingly using Xpert MTB/RIF (Xpert) testing as recommended by the WHO. \[[@pone.0236262.ref008]\] Following WHO guidelines, notification includes bacteriologically confirmed individuals and those clinically diagnosed in absence of positive tests or in absence of bacteriological test when it is unavailable. \[[@pone.0236262.ref009]\]

Multiple studies have documented significant individual patient and health system delays in TB diagnosis in Mozambique. \[[@pone.0236262.ref010], [@pone.0236262.ref011]\] People with TB often experience barriers to access the health facilities, first seek care from traditional healers, and/or visit health facilities several times before being tested and diagnosed with TB. This may partly explaining the gap between the actual number of people diagnosed and notified by the health system and the estimated number of people with TB in Mozambique. There is also a gap between the number of people diagnosed with and the number of people notified with TB--this is referred to as pre-treatment lost to follow-up (PTFLU). \[[@pone.0236262.ref010]--[@pone.0236262.ref014]\]

We hypothesized the following situations occurred in the districts where we worked: 1) a number of individuals with TB who present to health facilities are not diagnosed; 2) TB contact tracing could be optimized if Community Health Workers (CHWs) were given a role in it; 3) CHWs could identify individuals that are PTLTFU (people who are tested and have a positive laboratory test for TB, but are not subsequently informed of their results and do not begin treatment for TB) and 4) CHWs can help relink individuals that stop their anti-TB therapy or are lost to follow-up (LTFU) to care. We wanted to evaluate if interventions performed by CHWs to improve all these four weaknesses could lead to an increase in TB notifications at the district level.

Given the burden of TB and MDR/RR-TB, active case finding, improved diagnostics and access to treatment are a priority for the Mozambican National Tuberculosis Program (NTP) as part of an effort to reach the people with TB who are missed in Mozambique. As a result, Health Alliance International (HAI), a global health NGO with over 25 years of experience working in Mozambique, in partnership with the NTP, applied for and received funding for a TB REACH case finding project.

Methodology {#sec006}
===========

Through TB REACH funding, the Mozambican NTP and HAI employed thirty CHWs in five intervention districts of Manica Province (Gondola, Manica, Mossurize, Bárue, and Chimoio districts) where no other active case finding intervention was deployed. Candidates were identified, screened based on basic literacy and ability to use a smartphone, interviewed, and the final CHWs selected in partnership with district and facility TB supervisors and community leaders. They underwent a weeklong training using a ministry of health approved training package for TB CHWs which included instructions and a practicum about how to lead short TB sensitization sessions for all individuals presenting to and waiting for care at 14 health facilities (including the five district hospital/health centers and nine peripheral health centers) in the districts. CHWs were trained to perform systematic five symptom screening (persistent cough, weight loss, night sweats, fever or hemoptysis as recommended by the WHO) of all people entering these health centers and for household members of TB contacts. \[[@pone.0236262.ref015]\] People providing positive answers to symptom screening were referred for sputum sample collection and testing. Samples were analyzed by Xpert or smear microscopy depending on the availability in each facility. In addition to facility-based TB screening, the CHWs were trained in and also responsible for active contact tracing of people diagnosed and notified with TB through household visits where they also provided short TB sensitization sessions and WHO recommended symptom screening. CHWs worked with health facilities to identify individuals known to be PTLTFU or LTFU and then doing community based tracing to find and link these individuals to care. CHWs were supervised by the facility TB nurse, district TB supervisor from the NTP, and the project field supervisor. CHWs completed summary reports of their monthly activities which were reviewed and validated by the facility TB nurse and project field supervisor before being digitized.

Using routine NTP data we analyzed trends in quarterly TB notifications in the five Manica Province intervention districts (Gondola, Manica, Mossurize, Bárue, Chimoio--total population 1.8 million) and in seven Manica Province control districts (Sussendenga, Machaze, Guro, Tambara, Macossa, Macate, Vanduze--total population 1.6 million) in the 12 quarters (Q4 2014 through Q3 2017) before this project and during the four quarter intervention period (Q4 2017 through Q3 2018). Intervention and control districts were purposely selected by the provincial health department in an effort to focus CHW activities in districts with larger populations that may not have effective TB community partners. Control districts were selected among non-intervention districts and were characterized for not receiving any active TB case finding activity during the study and being roughly similar demographically and in terms of health care development to the intervention districts.

We analyzed and cross-referenced NTP data using monthly reports summarizing the activities of each individual CHWs that were based on a daily register of recorded activities. This CHW register captured: the number of TB sensitization sessions, the number of participants in TB trainings, a list of individuals with presumptive TB identified by the CHW, a list of individuals noted to be PTLTFU and LTFU who the CHW was responsible for tracing.

Analysis {#sec007}
--------

Routine NTP notification data was analyzed using a pre-post evaluation methodology of total TB and bacteriologically confirmed (B+) notifications in intervention and control districts. The analysis was part of the routine project monitoring and evaluation framework, and followed the standard TB REACH methodology to determine the impact of active case finding in notification and the additional number of people with TB that were notified and that could be attributed to the specific intervention. \[[@pone.0236262.ref016]\] The direct yield (TB cases found by CHWs) of the intervention was tracked using the reports from the CHWs and we evaluated the impact of the direct yield on overall NTP reported TB notifications (including passive case finding). We compared the number of new B+ and all forms of people with TB notified during the baseline period (Q4 2016 thru Q3 2017) to the notifications during the intervention period (Q4 2017 to Q3 2018) and then adjusted for historical TB notification trends during the previous three years (Q4 2014 thru Q3 2017) in both the intervention and the control districts. We estimated the expected notification during the implementation period in absence of intervention both in the districts where the project was implemented and in the control districts by applying linear regression to fit a trend line using the baseline notification data. Estimates were later compared with the actual notification values to measure the additional number of identified people notified with TB using a regression analysis and adjusting for historical trends. The relative changes in notifications in the intervention areas were further compared with the changes in notification in the control area between the same periods. This methodology is described in further detail elsewhere. \[[@pone.0236262.ref016], [@pone.0236262.ref017]\]

The intervention was approved by the National and Provincial TB Programs. Since the primary purpose of this evaluation was not research but to measure the increase the number of individuals notified with TB, and that the evaluation framework for this project and data analysis involved routine NTP data and project registries, formal review was not required by the University of Washington or Mozambican IRB.

Results {#sec008}
=======

During the four quarters of case-finding activities, the 30 CHWs led 6,737 TB sensitization sessions at facilities, in communities, schools and in TB contact households. This is approximately 19 sessions per CHW per month (or one per workday). CHWs reported that over 277,917 individuals participated in these sensitization sessions (some were at large public events attended by hundreds of people). As part of these sessions and active case finding activities CHWs identified 8,532 individuals with presumptive TB who they recorded in their registers, and successfully referred 7,921 (93%) for laboratory testing and/or clinical evaluation. Of these, 7,205 (84% of all people with presumptive TB) had a valid sputum smear microscopy or Xpert MTB/RIF test result. Eventually, 1,508 (18%) of all the presumptive individuals with TB were diagnosed with TB including 814 (54%) with bacteriological confirmation either by Xpert (577) or sputum smear microscopy (237). Almost all people diagnosed with TB as a result of this intervention started treatment (99.6%). The final yield of this intervention was 806 B+ individuals, and 1,502 people with all forms of TB diagnosed and enrolled in treatment.

The 30 CHWs also visited a total of 1,123 index case households, and 826 children less that 5 years old, who were contacts of individuals notified with TB and did symptom screening and referral for those who screened positive. Of the 826 children less than 5 years old, 703 were deemed eligible for and initiated TB preventive therapy with isoniazid. The number of people with active TB identified among household contacts and community case-finding activities was not recorded separately as part of this project, but routine NTP data shows that in the intervention districts as a whole less than 20% of individuals notified with TB were from contact tracing or community-based (not health facility-based) case finding activities.

During the study, the CHWs were also tasked with tracing 169 individuals who were pre-treatment lost to follow up (PTLTFU), of whom 148 (88%) were found, notified and started treatment for TB. The CHWs also identified 147 individuals who began but interrupted TB treatment, of whom 121 (85%) were found, relinked to care and restarted TB treatment. Process indicators for CHW TB activities are summarized in [Table 1](#pone.0236262.t001){ref-type="table"}.

10.1371/journal.pone.0236262.t001

###### TB Community Healthcare Worker (CHW) process indicators for thirty CHWs by quarter: Data reported by each CHW monthly based on their individual CHW TB activities register.

![](pone.0236262.t001){#pone.0236262.t001g}

  Indicator                                                                                                  Q4 2017     Q1 2018     Q2 2018     Q3 2018     Total
  ---------------------------------------------------------------------------------------------------------- ----------- ----------- ----------- ----------- -----------
  **Total number of CHW trainings at health facilities and in the community**                                1,073       1,725       1,984       1,955       6,737
  **Total Number of participants in CHW led trainings**                                                      40,531      76,871      79,821      80,694      277,917
  **Total Number of Presumptive TB Cases (Positive Symptom Screen) Identified by CHWs**                      1,267       2,195       2,653       2,417       8,532
  **Total number of presumptive TB cases referred for laboratory testing and clinical evaluation**           1,067       2,106       2,494       2,254       7,921
  **Total number of presumptive TB cases with a valid sputum smear or Xpert MTB/RIF test result**            914         1,831       2,306       2,154       7,205
  **Total number of presumptive TB cases that were sputum smear positive (and not tested by Xpert)**         52          87          50          48          237
  **Total number of presumptive TB cases there were Xpert MTB positive**                                     45          136         218         178         577
  **Total number of presumptive TB cases that were clinically diagnosed**                                    64          169         235         228         696
  **Total number of presumptive TB cases that were bacteriologically confirmed or clinically diagnosed**     161         392         503         452         1,508
  **Total number of sputum smear positive cases that were notified and started TB treatment**                49          87          50          47          233
  **Total number of Xpert MTP positives cases that were notified and started TB treatment**                  45          135         216         177         573
  **Total number of clinically diagnosed cases that were notified and started TB treatment**                 64          169         235         228         696
  **Total number of all bacteriologically confirmed or clinically diagnosed cases that started treatment**   158         391         501         452         1,502
  **Total number of notified TB cases that abandoned treatment**                                             35          29          53          30          147
  **Number of CHW led searches for abandoned cases**                                                         28          29          53          30          140
  **Number of abandoned cases that were relinked to care and restarted TB treatment**                        26          25          46          24          121
  **Number of pre-treatment lost of follow-up (PTLTFU) cases (diagnosed with TB, but not notified)**         42          63          22          42          169
  **Number of CHW led searches for PTLTFU cases**                                                            32          61          21          42          156
  **Number of PTLTFU cases that were linked to care and started TB treatment**                               31          59          18          40          148
  **Number of TB index case households visited by a CHW**                                                    166         283         375         299         1,123
  **Number of children \<5 that are household contacts of the index case that were screened for TB**         102         162         270         292         826
  **Number of children \<5 that were eligible for Isoniazid Prophylactic Therapy (IPT)**                     84          113         249         264         710
  **Number of children \<5 that started IPT**                                                                84          113         242         264         703
  **Calculated Percentages for Key Indicators**                                                              **Total**   **Total**   **Total**   **Total**   **Total**
  **Percentage of presumtive TB cases with a valid smear or Xpert laboratory result**                        85.7%       86.9%       92.5%       95.6%       84.4%
  **Percentage of presumptive TB cases that underwent TB testing with bacteriologically confirmed TB**       9.1%        10.6%       10.7%       10.0%       10.3%
  **Percentage of presumptive TB cases that were clinically diagnosed with TB**                              6.0%        8.0%        9.4%        10.1%       8.8%
  **Percentage of presumptive TB cases that had bacteriologically confirmed or clinically diagnosed TB**     15.1%       18.6%       20.2%       20.1%       19.1%
  **Percentage of bacteriologically confirmed TB cases that were notified and started TB treatment**         96.9%       99.6%       99.3%       99.1%       99.0%
  **Percentage of clinically diagnosed TB cases that were notified and started TB treatment**                100.0%      100.0%      100.0%      100.0%      100.0%
  **Percentage of all forms TB cases that were notified and started TB treatment**                           98.1%       99.7%       99.6%       100.0%      99.6%
  **Percentage of patients that abandoned treatment that were traced by CHWs and restarted TB treatment**    92.9%       86.2%       86.8%       80.0%       86.4%
  **Percentage of PTLTFU cases that were traced by CHWs and restarted TB treatment**                         96.9%       96.7%       85.7%       95.2%       87.6%
  **Percentage of children eligible for IPT that started IPT**                                               100.0%      100.0%      97.2%       100.0%      99.0%

Q = Quarter

Impact on notification {#sec009}
----------------------

The year prior to the intervention 2,277 B+ and 5,219 all forms of TB were notified in the intervention area and 945 B+ and 2,248 all forms of TB in the control area. During this yearlong study, the numbers of notifications increased to 2,933 B+ and 5,982 all forms of TB (an increase of 656 B+ or 28.8% and 763 all forms or 14.6% respectively) in intervention districts. In contrast the number of notifications in control districts during this yearlong study fell to 806 B+ and 1877 all forms of TB (a decrease of 139 or -14.7% and 371 or -16.5% respectively). These results are summarized in [Table 2](#pone.0236262.t002){ref-type="table"}.

10.1371/journal.pone.0236262.t002

###### TB notifications in intervention and control districts during the implementation period, historical baseline and expected notifications: Estimation of additionally notified individuals with TB.

![](pone.0236262.t002){#pone.0236262.t002g}

                           Notifications         Implementation period   Historical baseline   Expected notification according to trend   Additionally notified persons with TB (unadjusted)   \% of increase in notification (unadjusted)   Additionally notified persons with TB (adjusted)   \% of increase in notification (adjusted)
  ------------------------ --------------------- ----------------------- --------------------- ------------------------------------------ ---------------------------------------------------- --------------------------------------------- -------------------------------------------------- -------------------------------------------
  Intervention districts   New Pulmonary Bac +   2933                    2277                  2711                                       656                                                  28.8%                                         222                                                8.2%
  All forms of TB          5982                  5219                    5860                  763                                        14.6%                                                122                                           2.1%                                               
  Control districts        New Pulmonary Bac +   806                     945                   1203                                       -139                                                 -14.7%                                        -397                                               -33.0%
  All forms of TB          1877                  2248                    2850                  -371                                       -16.5%                                               -973                                          -34.1%                                             

When controlling for the notification trends for the previous three years, B+ notifications in the intervention districts were 2,933 B+ compared an expected value of 2,711 B+ meaning a moderate increase of 222 additional people with B+ TB notified or an 8.2% increase compared to the historical trend. Similarly, the intervention districts notified 5,982 individuals with all forms of TB over an expected value of 5,860, leaving a net increase of 122 individuals with TB or a 2.1% increase.

In contrast, in the control districts, given the historical trend, the expected values were 1,203 Bac+ and 2,850 individuals notified with all forms of TB, while the actual notification showed only 806 Bac+ and 1,877 all forms; 397 or -33% and 973 or -34.1% less than expected. These results are summarized in [Table 2](#pone.0236262.t002){ref-type="table"}.

The additional notification / yield ratio for B+ individuals is 0.8 and 0.5 for all forms (see [Table 3](#pone.0236262.t003){ref-type="table"}) meaning not all individuals with TB yielded by CHWs (806 Bac + and 1,502 all forms of TB) could be directly translated into additional TB notifications (656 Bac + and 763 All forms of TB).

10.1371/journal.pone.0236262.t003

###### Project generated yield and additionally notified individuals with TB.

![](pone.0236262.t003){#pone.0236262.t003g}

                        Yield   Additionally notified persons with TB (unadjusted)   additionality/Yield
  --------------------- ------- ---------------------------------------------------- ---------------------
  New Pulmonary Bac +   806     656                                                  0.8
  All forms of TB       1502    763                                                  0.5

More detailed graphs of the historical trends and expected vs actual notifications are included as an annex, along with the underlying data sets.

Discussion {#sec010}
==========

This practical TB case-finding implementation study used routine NTP and project data to evaluate a CHW facility-based and contact tracing TB case-finding project with intervention and control districts in Manica Province, Mozambique. The results showed a significant increase in TB notifications in the intervention districts in comparison to historical and contemporary controls. Of the individuals with TB identified by CHWs, 54% were Bac+, while nationally in Mozambique the rates are less than 40%. This was likely due to more active TB case finding and screening from CHWs, leveraging health facility based TB testing including smear and recently deployed Xpert systems. \[[@pone.0236262.ref001], [@pone.0236262.ref018]\]

The use of the additionality to yield ratio is also of interest. Often, interventions only identify the numbers of people detected without assessing whether or not the intervention had any impact on notifications, others may report additionally notified people with TB without looking at the direct yield of the intervention itself. The ratio between additionality and yield provides a sense of how much the intervention adds to routine practice in terms of notification increases. A ratio closer to one might only be seen in prisons or populations that had no access to services previously, while a ratio closer to 0 would mean that the intervention was not really identifying more people with TB, maybe just detecting them slightly earlier. The fact that the additional numbers of notified individuals with TB is higher among the B+ than among all forms of TB (0.8 vs 0.5) suggests that some "transference" of individuals with TB that would be previously classified as clinically diagnosed and counted in all forms of notified TB, are now B+ given Xpert's superior sensitivity. \[[@pone.0236262.ref019]\] Active case finding projects will often diagnose more B+ individuals if outreach is the main intervention and people screened do not have easy access to clinicians who can diagnose them in lieu of microbiological evidence. \[[@pone.0236262.ref020], [@pone.0236262.ref021]\] As noted in [Table 3](#pone.0236262.t003){ref-type="table"}, it is estimated that only a proportion of individuals with TB identified by the project (roughly 80% of the Bac+ and 50% of all forms) actually led to the overall increase in the number of people with TB notified. The remaining likely would have found their way to diagnosis and treatment through the passive notification system even in absence of the project. However, they would have been diagnosed later, and potentially at greater cost to them and in a poorer state of disease. \[[@pone.0236262.ref022], [@pone.0236262.ref023]\]

Study limitations include that both intervention and control districts were not randomly selected and may not be representative of all Mozambican health facilities. The existence of differences between intervention and control districts that could explain the results besides the exposure to the intervention cannot be completely excluded. Using historical notification data to control for trends may not necessarily project what would happen in the future. In addition, individuals with presumptive TB were not disaggregated by coming from a facility, the community, or TB contacts, limiting the ability to fully analyze these different interventions. The decrease in notified cases in control districts is not exceptional in long term notification trends and may be due to cyclical changes in health seeking behavior and/or health services response, which may have also occurred in the intervention district in the absence of the project.

As part of a large global push to increase the numbers of people with TB diagnosed, notified and treated, \[[@pone.0236262.ref024]--[@pone.0236262.ref027]\] our results make relevant contributions. Despite the presence of TB services at the major health facilities in these intervention districts, this project demonstrated a significant gap in the true number of people with TB who are presenting to these health facilities and those who are eventually diagnosed and notified. [Table 1](#pone.0236262.t001){ref-type="table"} showed how CHWs worked to bring back 148 people (or 88%), out of 169, that had been diagnosed but were lost before treatment initiation, a positive finding of CHW performance also documented elsewhere. \[[@pone.0236262.ref020], [@pone.0236262.ref021], [@pone.0236262.ref028]--[@pone.0236262.ref033]\] During the period of this intervention less than 20% of total TB notifications in the intervention districts from contact tracing and community-based active case finding, suggesting that intensified facility-based screening using CHWs explained most of the increased notification. Given our study design, it is not possible to define which intervention within the different activities CHW performed in and sometimes outside health facilities produced more of the additionally notified individuals, but it is clear that together there was an increase of people with TB diagnosed, and that they were more likely to be B+. Facility-based screening is certainly lower cost when compared to active outreach, but activities such as contact investigation remain critical to meet targets for both case finding and is essential to start TB preventive therapy. Focused active case finding, particularly using facility-based CHWs, can improve the number of people who are detected and treated for TB and can push towards the ambitious targets of the WHO's End TB Strategy and the recent United Nations High level Meeting on TB. \[[@pone.0236262.ref024]\]

Historically, Mozambique has relied on passive case-finding strategies for TB, and individuals self-presenting to health facilities. There have been various community TB CHW activities, but these have been fragmented, involved different strategies, and did not utilize a standardized monitoring and evaluation (M&E) framework. As recommended by the WHO and others \[[@pone.0236262.ref034]--[@pone.0236262.ref036]\], this has started to change with specific projects supported by USAID such as the recent Challenge TB (CTB) Project in Sofala, Nampula, Tete and Zambezia provinces. TB notifications increased substantially during the recent CTB project which has a strong CHW community TB-case finding element, but most of the additional individuals were not B+, which is surprising given the recent scale-up of LED microscopy and Xpert MTB/RIF testing in Mozambique. \[[@pone.0236262.ref037]\] An international NGO called JHPIEGO has also been leading a "cough officer" project that trains health facility janitors and lay employees to do some facility-based active TB case-finding. \[[@pone.0236262.ref037]\] Given the results of the CTB project, the cough officer project and this project, and combined greater acknowledgement about the need for more active TB case-finding strategies in Mozambique, the NTP contracted a local Mozambican NGO to provide community TB activities in six additional provinces where CTB was not located, including Manica province with support from their recent Global Fund award. The CHW registries and M&E framework from this TB REACH project, along with instruments from CTB and JHPIEGO were adapted by a new NTP led TB CHW working group to develop the first national CHW TB guidelines in Mozambique, along with a national and standardized M&E framework for all TB CHW partners.

Conclusion {#sec011}
==========

While overall TB notifications increased in Mozambique over the past 8 years this has been primarily driven by increases in clinically diagnosed TB, and the overall trend in TB notifications is starting to plateau. This practical TB case finding implementation study using routine NTP and project data shows that a CHW facility based and contact tracing TB case-finding strategy may significantly increase TB notifications, particularly those that are bacteriologically confirmed, in central Mozambique.
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If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study in the Author Contributions section of the online submission form. Please make any necessary amendments directly within this section of the online submission form.  Please also update your Funding Statement to include the following statement: "The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If the funding organization did have an additional role, please state and explain that role within your Funding Statement.

Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

5\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6\. Please amend the manuscript submission data (via Edit Submission) to include author M Chidacua.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: It does appear that this intervention had a substantial beneficial impact, however I have many questions. Some of these are requests for clarification, others are more substantive.

Line 54: Readers might want a brief explanation of how WHO estimates the incidence rate of TB.

Line 59: We would want to see a brief explanation of the notification system. How does this work? By implication it appears to be operated by the NTP but who are the reporters? Since it appears that not all notified cases are laboratory confirmed what are the criteria?

Line 76: Answers to the above might help us understand why there is a gap between diagnosed and notified cases.

Line 89: I would like to see a fuller description of the training the CHWs received. How are they recruited? What are their initial qualifications? How many hours of training do they undergo? Is there a manual? Are there certification requirements? How are they supervised?

Line 91: Please explain \"five symptom screening.\"

Line 102: You should say something in the discussion about the differences between the intervention and control districts. That these were not randomly selected is a limitation of the study. You say there was no active case finding in the control districts but was there already active case finding in the intervention districts apart from the CHW intervention? What are other differences?

Line 115: Please explain the TB REACH methodology.

Line 122: What do you mean by secular notification trends? How were these extracted from the observed trends? That you refer to description of the methodology elsewhere is not sufficient, you need to at least explain the basics of what you did here. It is not clear where you actually report the difference between the observed and expected changes in notification based on the \"secular\" trend.

Table 2: One of the column labels is in Portuguese.

Line 173: It is surprising that the number of notifications in the control districts fell during the study period. You should at least offer some speculative explanations for this in the discussion.

Line 175: You refer to a regression analysis but you say nothing about it. What kind of regression? Again, where do the \"secular trends\" come from? Why are notifications in the control area an independent variable in this regression? I do not understand the reported results, that B+ notifications increased by 1.44 times, for example. This is not the usual interpretation of a regression coefficient.

Line 182. I do not understand this discussion of the \"notification/yield\" ratio. I thought notifications were your only outcome variable. What does the unnotified yield consist of and how is it ascertained? This also means that the discussion beginning at line 205 is indecipherable. What do you mean by additionality vs.yield? If cases are not reported how do you know they exist?

Line 229: What does JHPIEGO stand for?

Line 242: You say there is a gap between the true number of TB cases presenting to health facilities and those that are diagnosed and reported, but you do not explain how you know this. You go on to say that you do not know which intervention produced more of the additional cases but on lines 139 et seq it appears that you do disaggregate contact tracing and community based case finding from clinic-based ascertainment.

Line 266: You say that presumptive TB cases were not disaggregated as coming from a facility the community or TB contacts but again I thought you had reported these distinctions in detail starting around line 139.

In sum, I think this is likely a good contribution but you need to explain it much better.

Reviewer \#2: Strength:

A well designed pragamatic study to assess an important screening intevention in facilities using CHW. The manuscripts answers an important TB research question and will contribute knowledge on how to increase case detection at facility. Studies have shown TB patients had visited facilities on several occasion before a TB diagnosis. Appropriate analysis and use of standardized evaluation framework

Weakness:

Multiple intervetions on case detection were going on or had been done in these study areas. Although the authors have discussed these in their discussion, it remains a weakness and consider revising the conclusion from \....can lead.. to \...may lead\...

Specific comments

74 'Multiple studies have documented significant patient and health system delays in TB

75 diagnosis in Mozambique'..this sentence needs to be referenced

143 Using the TB REACH terminology, the yield of this\...The terminology needs to be defined in the methods

Reviewer \#3: Using Lay Health Workers for Facility and Community Based TB Case Finding: An

Evaluation in Central Mozambique

TB case finding is a priority for many countries which have lower treatment coverage. The use of community health care workers to supplement efforts by NTP is crucial to close the missing gap. CHW have the potential to improve TB case finding by conducting community active case finding especially on bacteriologically confirmed contact. The paper is important to increase the body of evidence of CHW role in TB control efforts. But there are few issues that need to be addressed to bring this paper to the required quality and better inform the TB community on the contribution of CHW on TB case finding.

GENERAL COMMENTS

• Change the language from cases to TB patients were appropriate to confirm to non-stigmatizing language.

• The paper, in some areas, misses the logical sequential flow of idea. It may difficult for some readers to follow the authors main story.

• Clearly define the main objective and exploratory objectives, as the way they are written now, they are given equal emphasis which can be a bit confusing.

SECTION SPECIFIC COMMENTS

Title: proposed to maintain community healthcare workers rather than lay health workers. The lay health workers have not referred anywhere else in the manuscript.

ABSTRACT:

Line 27-28: "Mozambique has one of the highest rates of both TB and HIV in the world 28 but an estimated TB treatment coverage of only 57% in 2018". Needs clarity of the whether talking about incidence or mortality? Also consider rephrasing the sentence.

Line 39: The CHW screening activities yielded 1,502 notified and treated TB cases. The increase in the TB patients notified is only 763, please clarify why the different numbers?

Line 39-40: as we are looking for additionality of the intervention as compared to before the intervention, the correct number should be 763 and should be written and then the percentage.

Line 39-40: the 1,502 is this number compared to baseline, or this is the number of TB cases contributed by CHW during the intervention period. This has to be clear.

INTRODUCTION

General comment

• There is no flow as there is no connection between sentences/there is a no story line for the reader to follow what the authors want to communicate.

• I think the references are before the full stop and not after. Please review the manuscript and change accordingly.

• The article talks about the effect of CHW in increasing TB case finding, not even a single literature that highlight the effect of CHW in overall case finding is other areas with similar TB epidemiological profile.

• I seem to miss the primary objective of the

Line 52: put the abbreviation of TB here and not in line 54. It makes sense to put the abbreviation in the first use of the word in question.

Line 55: the authors are already talking about Mozambique; it is kind of a repetition to again mention Mozambique. Also, consider rewriting this sentence... "resulting in 162,000 new cases each year". Authors can consider to rewrite the sentence into something like "...translating to an estimated 162,000 new TB patients".

Line 56-58: "This has been largely fueled by the HIV epidemic with a national 57 prevalence of 13.2%, but compounded by deep poverty with an estimated average 58 gross national income per capita of only \$440 USD". Please rewrite this sentence. Keep it simple, and separate each part and explain it clearly. This has been largely, what exactly? Consider starting a sentence like, TB is largely fueled by high HIV epidemic of 13.2%, poverty ......" Also, the word deep poverty has not objective measurement to a reader, it is just open to too much interpretations which are not standard.

Line 58-60: "Of the estimated incident TB 59 cases, 92,381 were diagnosed and notified in 2018 resulting in a treatment coverage 60 rate of only 57%". The sentence should go after end of Line 56 which talks about WHO estimated TB incidence rate. This is a logical flow when authors want to talk about treatment coverage.

Line 68-73: authors to consider making this the last paragraph of your introduction section.

Line 74-85: these are just too many hypotheses which seem not be related to the CHW role. I am curious to how you managed to test all these hypotheses. Also, the hypothesis lacks direction in terms whether increasing or decreasing your outcomes of interest.

METHODS

• Define the content of training package to CHW which includes the topics covered, for how many days and conducted by who. Was there any proficiency testing done to ensure the understanding of the CHW?

• The paragraphs have mixed information on study setting, population, data collection and study procedures. The authors can consider separating these into clear headings for easy of the readers to understand.

Ethics statement

Ethics statement was only waived from University of Washington IRB. What about local or national ethics bodies in Mozambique? Was there no waiver applied to these ethics bodies as the research was done there?

Study setting

Study population and study definitions

Laboratory investigation

Need to mention the laboratory procedures used to confirm for TB.

Statistical analysis

I am missing the statistical analysis of the effect of interventions within the clusters and comparison between intervention and control areas.

Line 128: the bracket is out of place.

RESULTS

General comments of results section

• Need consistency of reporting if putting numbers and proportions for each sub-population accessing a certain service.

• Intervention and control areas: consider additional tables (supplement) to describe the baseline characteristics of the intervention and control areas. You may include notification, population size and availability of diagnostic services (smear microscopy and Xpert).

• Table 1: is a bit difficult to read and make out the numbers and proportions. The table has been copied from excel and pasted here, I would suggest you have a Microsoft word table. The absolute numbers and proportions are separate, making the reading of this table difficult.

Line 137-143: consider having a flow diagram for the readers to understand the

Line 137: consider revising the text to "... CHWs identified 8532 presumptive TB patients...."

Line 138: consider adding proportion of the presumptive TB patients sent for laboratory testing

Line 140: what do you mean valid sputum smear microscopy or Xpert MTB/RIF test? So, 16% of the tests had invalid results or they had negative results?

Line 140: "... 1508 (18%) of the ..." are these a sub-population of presumptive TB patients either tested for TB for of all presumptive TB patients? Consider to be specific of denominators when presenting the results of TB care cascade.

Line 143: "Using the TB REACH terminology..." is not just the additional TB patients from the intervention? Is it really a TB REACH terminology? Or is it necessary to mention that? The TB community would understand yield or additional TB patients.

Line 144: the 1,508 all forms of TB notified from the intervention group, is different from line 39 in the abstract section which is 1,502 TB notified of all forms.

Line 145: ".. and 286 contacts of TB were notified .." I think the use of the word notified for contacts is not appropriate. I would reserve for TB patients. authors can consider using the words like reported, identified etc.

Line 178: there is mention of regression analysis which is not mentioned in the statistical analysis under methods.

Line 148-154: these are the findings from the implementation period and lacks any comparison either from the control, or the intervention period? We need some sort of baseline data to compare the effect of CHW on PTLTFU and LTFU. What were your hypothesis in terms of direction on these outcomes?

DISCUSSION

• The discussion section was expected to comment on the decreased TB notification from control districts. Why is that? What is common among the control districts that affected case finding during the project period?

• Were there any concurrent interventions that were implemented during the implementation of The TB REACH project in the intervention districts?

• Are the results consistent with other CHW efforts in other settings with similar background epidemiological profile? There are many research outputs from many settings that will better inform the performance of this Mozambique experience, but those references are missing in this paper.

• Line 266-268: reading from methods and part of the methods section, I had the impression that all presumptive TB patients were registered in the CHW registers based on the interventions done by CHW. So why the authors would not be able to fully analyze these different interventions? Authors need to clarify.

• I am not sure of the role of JHPIEGO and CTB in this project. Line 229-239 is more of lessons learnt and its impact in Mozambique in developing CHW TB guidelines. Authors need to consider to shorten this section, and if need be present this additional information in the supplement text. JHPIEGO, write in long form.

• Line 240-262: part of the discussion on the yield should go to the first two paragraphs and discuss more the results and compare with other settings.

REFERENCES

General remarks

• The name of organization or institutions should be written in full, and they are not shorted as individual names. Please check the following:

• Online reference can be made on the web references only? Please check all the references and see if they fit the journal guidelines.

Check reference no. 4. What is "Bank W"?

Check reference no. 15. What is "Partnership. ST"?
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Author response to Decision Letter 0

27 May 2020

Dear PLOS Medicine Editorial Team,

It is our pleasure and privilege to submit this rebuttal letter for the associated manuscript "Using Community Health Workers for Facility and Community Based TB Case Finding: An Evaluation in Central Mozambique". We are grateful for your teams detailed comments which we have responded to below and we have incorporated relevant changes in the manuscript.

Thanks for your consideration and please let us know if you have any questions or comments.

Sincerely,

James Cowan MD, MPH, MBA

Journal Requirements

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming.

Done.

2\. Please include in your Methods section (or in Supplementary Information files) the participating hospitals/institutions and the districts where the intervention was used. Please also describe in more detail how the intervention sessions were conducted, including how many patients participated.

The five intervention districts in Manica province are: Gondola, Manica, Mossurize, Bárue, and Chimoio districts. We worked in each of the district hospital/health centers and nine peripheral health centers. We have updated this language in the text.

If you would like to know the home health facility of each CHW they are the following and can be added as an annex is desired: Centro de Saude (CS or "Health Center") Chissui, CS 7 Abril, CS Ed Mondlane, CS Nhamaonha, CS Vila Nova, CS 1 Maio, CS Dacata, Hospital Distrital Mussorize, Hospital Distrital Goi Goi, CS Mude, CS Chiurairwe, CS Penhalonga, CS Messica,CS Mavonde, CS Jecua, CS Machipanda, Hospital Distrital Manica, Hospital Distrital Manica, CS Chitunga, CS Amatongas, CS Inchope, Hospital Distrital Gondola, CS Chipindaumwe, CS Muda Seracao, CS Nhassacara, Hospital Distrital Barue, CS Nhazonia, CS Honde, CS Nhanpassa.

We provided some additional details how the intervention sessions were conducted, using WHO recommended symptom screening and contact tracing.

In the results section we explained that on average that each CHW led 19 sessions per month, and that over 277,000 individuals participated in these sensitization sessions. Of these 8,532 were identified as presumptive TB cases, with at least one positive result on symptom screening.

3\. Thank you for stating in your Funding Statement:

\"This research was supported in part by a grant from the Stop TB Partnership's TB REACH initiative which is funded by the Global Affairs Canada, the Bill and Melinda Gates Foundation and USAID. This research was funded in part by a 2015 developmental grant from the University of Washington Center for AIDS Research (CFAR), an NIH funded program under award number AI027757 which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Jacob Cresswell and Zhi Zhen Qin are employees of the Stop TB Partnership and oversee the TB REACH grant portfolio which supported this project. They were not involved in project implementation but did provide general project oversight. In addition, they reviewed and provided comments of this article - for this they are listed as co-authors.\"

Please provide an amended statement that declares \*all\* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>. Please also include the statement "There was no additional external funding received for this study." in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

We provided an updated Funding Statement in the cover letter, and the same statement in the funding section of the manuscript. Please let us know if this is adequate.

4a. Thank you for providing the following Funding Statement:

\"This research was supported in part by a grant from the Stop TB Partnership's TB REACH initiative which is funded by the Global Affairs Canada, the Bill and Melinda Gates Foundation and USAID. This research was funded in part by a 2015 developmental grant from the University of Washington Center for AIDS Research (CFAR), an NIH funded program under award number AI027757 which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Jacob Creswell and Zhi Zhen Qin are employees of the Stop TB Partnership and oversee the TB REACH grant portfolio which supported this project. They were not involved in project implementation but did provide general project oversight. In addition, they reviewed and provided comments of this article - for this they are listed as co-authors.\"

We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors.

If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study in the Author Contributions section of the online submission form. Please make any necessary amendments directly within this section of the online submission form. Please also update your Funding Statement to include the following statement: "The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If the funding organization did have an additional role, please state and explain that role within your Funding Statement.

Thank you. We have updated the funding statement in the Cover Letter, the manuscript and the authors contribution section. We have clarified that Global Affairs Canada, The Bill and Melinda Gates Foundation, USAID and the NIH are the "funders". We are not considering the Stop TB Partnership or TB REACH a "funder" but an initiative or a pass-through mechanism. The funders provided salary support for JCresswell, ZZQ and JCowan but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

4b. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

No authors report any competing interests. Thus, this does not alter our adherence to PLOS ONE policies on sharing data and materials.

4c. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please see response to 4b.

4d. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Noted. Please see response to 4b.

5\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

After discussing internally, we are comfortable sharing the data. In general, the TB Program Manager in Mozambique would like to be informed when any non-Mozambique Ministry of Health organization is accessing and analyzing TB data from Mozambique. If possible we would request that any group accessing this data please, as a courtesy inform Dr. Ivan Manhiça at <ivanmca2004@yahoo.com.br> particularly if they have plans to share or publish additional findings.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Please see response to \#5.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will upload an excel with the core data and our analysis.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Agreed.

6\. Please amend the manuscript submission data (via Edit Submission) to include author M Chidacua.

Done. 

Response to reviewers

Reviewer \#1: It does appear that this intervention had a substantial beneficial impact, however I have many questions. Some of these are requests for clarification, others are more substantive.

Line 54: Readers might want a brief explanation of how WHO estimates the incidence rate of TB.

WHO produces annually national estimates of incidence for all countries which are then internationally used to calculate the gap between estimated incidence and actual notification. It declares these "estimates of TB incidence are produced through a consultative and analytical process led by WHO and are published annually \[and are\] based on annual case notifications, assessments of the quality and coverage of TB notification data, national surveys of the prevalence of TB disease and on information from death (vital) registration systems. Uncertainty bounds are provided in addition to best estimates. Details are available from" Policy and recommendations for how to assess the epidemiological burden of TB and the impact of TB control and Annex 1 of the WHO global tuberculosis report\" . In consequence, we added a short sentence in the manuscript summarizing this explanation for readers.

Line 59: We would want to see a brief explanation of the notification system. How does this work? By implication it appears to be operated by the NTP but who are the reporters? Since it appears that not all notified cases are laboratory confirmed what are the criteria?

Cases are diagnosed and notified in health facilities. They are either (a) clinically diagnosed because access to tests was not available at the time or because they were negative while the clinical and epidemiological criteria made the clinician consider TB as the most likely diagnosis (based on history, contact, physical exam, chest imaging etc -- guidelines on how to make a clinical diagnosis are outlined in the Mozambique TB Guidelines), or (b) bacteriologically confirmed. The causes of the gap between incident cases and notified cases is multifactorial. In our article we try to show how active case finding using CHW can recover cases which would have been part of the gap. We expanded the explanation later in the section hoping to provide a clearer explanation to the reader. Notification follows the definitions and reporting framework established by WHO and we added a reference to it.

Line 76: Answers to the above might help us understand why there is a gap between diagnosed and notified cases.

See our reply to question mentioned for Line 59.

Line 89: I would like to see a fuller description of the training the CHWs received. How are they recruited? What are their initial qualifications? How many hours of training do they undergo? Is there a manual? Are there certification requirements? How are they supervised?

This project employed one main clinical supervisor who had a decade of experience providing TB care and supervisory services in Manica Province, Mozambique. This individual worked with clinicians, facility level TB nurses, and community leaders to identify potential TB CHWs in each district and in each of 14 participating health centers and hospitals (some of these candidates had worked on previous CHW project, and many were TB survivors). He then led interviews of candidates with these key partners and the district TB supervisor.

Candidates needed to have equivalent of an 8th grade education, to be literate, have the capacity to operate a smart phone, do basic math and to be able to manage a written TB registry of presumptive TB cases. Each CHW underwent a week of training using a NTP approved training package for CHWs. The project supervisor provided a minimum of monthly in-person supervision visits, and frequently more to each CHW to review their written registries and to discuss cases. We also maintained a WhatsApp group for all CHWs and the supervisor to share best practices, for CHWs to request support for complex situations, and to disseminate updated guidance. Over the course of this project 4 CHW either left their position for personal reasons or were not regularly reporting for work and were fired after consultation with MOH district supervisors. They were all rapidly replaced, and these replacements underwent similar training.

In addition to the study supervisor, these 14 health centers also had a local TB nurse, and there is also a district TB supervisor as part of the ministry of health. On a weekly basis the CHWs also reported to these individuals, who were required to review, and sign off on the monthly summary report that the CHWs submitted to their supervisor. These reports were digitized and then served as the basis for the database analyzed by this study, along with routinely reported facility level TB data that flowed through the MOH reporting system.

Line 91: Please explain \"five symptom screening.\"

It refers to verbal symptom screening to individuals actively asking explicitly about the presence of at least one of the following symptoms within the previous two weeks: (1) cough for more than a week; (2) weight loss, (3) night sweats, (4) fever or (5) hemoptysis. This was recommended by the WHO and we are including the reference in the revised manuscript. World Health Organization. Systematic Screening for active tuberculosis: principles and recommendations. Geneva. World Health Organization, 2013.

Line 102: You should say something in the discussion about the differences between the intervention and control districts. That these were not randomly selected is a limitation of the study. You say there was no active case finding in the control districts but was there already active case finding in the intervention districts apart from the CHW intervention? What are other differences?

Intervention and control districts could not be randomly selected and we acknowledge that is a weakness of the study and we include it in our discussion. However, control districts were selected among districts where there was no active case finding in process and were demographically and socially roughly comparable with our intervention area, including a similar level of health care deployment. There was no other active case finding activity apart from our CHW project in our intervention area. We added an explanation in the methodology and in the discussion.

Line 115: Please explain the TB REACH methodology.

The TB REACH methodology is comprehensively reviewed in the references quoted. Essentially, it compares notification in pre and during the intervention time periods and calculates additional notifications above what could be expected if the historical notification trend would be maintained over time. It also compares the evolution of the notification trends in the evaluation population, where it is expected to grow if the intervention is effective, against the evolution in the control population, where it is expected to continue its historical trend. We expanded the explanation in the revised manuscript to make it clearer to the reader.

Line 122: What do you mean by secular notification trends? How were these extracted from the observed trends? That you refer to description of the methodology elsewhere is not sufficient; you need to at least explain the basics of what you did here. It is not clear where you actually report the difference between the observed and expected changes in notification based on the \"secular\" trend.

The historical notification trend (or the secular notification trend) in the last three years both in the intervention and the control districts for the bacteriologically confirmed new cases of TB and for all forms is used to predict the expected values for the implementation period in absence of the intervention. These estimations are then compared with the true notification over the implementation period. We have updated and tried to explain this better in the manuscript.

Table 2: One of the column labels is in Portuguese.

Thank you. This is corrected.

Line 173: It is surprising that the number of notifications in the control districts fell during the study period. You should at least offer some speculative explanations for this in the discussion.

These oscillations in long term notification trends are not exceptional. In fact, a similar low can be identified in the period Q4 2015-Q2 2016 (see figures from the annex) and can be related to changes in health seeking behavior and/or overall relaxation in the mainstream health system or in the notification system. We add an explanation in the discussion.

Line 175: You refer to a regression analysis but you say nothing about it. What kind of regression? Again, where do the \"secular trends\" come from? Why are notifications in the control area an independent variable in this regression? I do not understand the reported results, that B+ notifications increased by 1.44 times, for example. This is not the usual interpretation of a regression coefficient.

We updated the description of the analysis and we hope it is now clearer and simpler. We introduced a new table which we hope better summarizes the results.

Line 182. I do not understand this discussion of the \"notification/yield\" ratio. I thought notifications were your only outcome variable. What does the unnotified yield consist of and how is it ascertained? This also means that the discussion beginning at line 205 is indecipherable. What do you mean by additionality vs. yield? If cases are not reported how do you know they exist?

In this project, as in any active case finding project, we cannot claim all the cases identified by the project would have not been diagnosed without the project deployment. Even in the most adverse conditions in the weakest health system, some cases are always diagnosed. In that sense, we cannot claim that all the cases identified by the project can be counted as an additionally notified case.

We try to measure this fact with the "additional notification/yield" ratio. The numerator is the difference between the actual notified cases during the project implementation minus the notification that could be expected. The denominator is the number of TB cases identified by the active case finding project. The logic is that if all the yielded cases were truly additional notification the ratio would be 1. The result in our project, as in most projects of this type, is below 1, meaning only this proportion of the total cases identified could eventually be considered as additional. The methodology is fully explained in the references quoted in the manuscript.

We improve our explanation here and also in line 205 hoping it becomes clearer to readers and introduced this table.

Line 229: What does JHPIEGO stand for?

JHPIEGO is an international non-profit organization affiliated with Johns Hopkins University (JHU) and was initially called Johns Hopkins Program for International Education in Gynaecology and Obstetrics (JHPIEGO). Since its creation its interest grew outside its initial scope but the name remained and is used without reference to its prior meaning. We added a short insert in the text making reference to its NGO character.

Line 242: You say there is a gap between the true number of TB cases presenting to health facilities and those that are diagnosed and reported, but you do not explain how you know this. You go on to say that you do not know which intervention produced more of the additional cases but on lines 139 et seq it appears that you do disaggregate contact tracing and community-based case finding from clinic-based ascertainment.

\(a\) In table 1, we could present the results of how many TB cases that had been diagnosed and were lost to follow up before treatment initiation, namely 148 out of 169 (88%). It is in that sense that we can say that the gap exists and that our project was operational in reduce it. We try to explain it better in the text.

\(b\) What we meant is that it was impossible to disentangle which of the CHW activities (i.e. (1)TB sensitization sessions for patients waiting at 14 health facilities, (2) active five symptom screening of people attending at all clinical sites (3) contact tracing of identified TB cases through household visits, (4) tracing PTLTFU cases and (5) tracing people that are LTFU in order to relink them to care) produced more additionally notified cases. The statement does not contradict that in the districts as a whole, according to the notification registration data, the percentage of cases identified by contact tracing and community (meaning, outside health facilities) active case finding remained similar reinforcing the view of the impact of activities CHW performed within facilities. We try to be clearer in the text.

Line 266: You say that presumptive TB cases were not disaggregated as coming from a facility the community or TB contacts but again I thought you had reported these distinctions in detail starting around line 139.

You are right we had made a description of what CHW did in around line 139 but we could not link the impact of each one of these different activities in notification. We clarify it in the text.

In sum, I think this is likely a good contribution but you need to explain it much better.

Thank you for all your comments. We hope we have been able to use all of them to improve our manuscript.

 

Reviewer \#2: Strength:

A well-designed pragmatic study to assess an important screening intervention in facilities using CHW. The manuscript answers an important TB research question and will contribute knowledge on how to increase case detection at facility. Studies have shown TB patients had visited facilities on several occasion before a TB diagnosis. Appropriate analysis and use of standardized evaluation framework

Weakness:

Multiple interventions on case detection were going on or had been done in these study areas. Although the authors have discussed these in their discussion, it remains a weakness and consider revising the conclusion from \....can lead.. to \...may lead\...

We appreciate the comment and adjusted the conclusion statement.

Specific comments

74 'Multiple studies have documented significant patient and health system delays in TB diagnosis in Mozambique'. This sentence needs to be referenced

Yes, references are quoted now in the end of this sentence.

143 Using the TB REACH terminology, the yield of this\...The terminology needs to be defined in the methods

We hope that the changes introduced in the methodology section clarify the terminology. We have also taken out the mention to "using the TB REACH" terminology" in this particular sentence as we understand it does not add any value to the statement.

 

Reviewer \#3: Using Lay Health Workers for Facility and Community Based TB Case Finding: An

Evaluation in Central Mozambique

TB case finding is a priority for many countries which have lower treatment coverage. The use of community health care workers to supplement efforts by NTP is crucial to close the missing gap. CHW have the potential to improve TB case finding by conducting community active case finding especially on bacteriologically confirmed contact. The paper is important to increase the body of evidence of CHW role in TB control efforts. But there are few issues that need to be addressed to bring this paper to the required quality and better inform the TB community on the contribution of CHW on TB case finding.

GENERAL COMMENTS

• Change the language from cases to TB patients were appropriate to confirm to non-stigmatizing language.

We change the language to abide to non-stigmatizing language.

• The paper, in some areas, misses the logical sequential flow of idea. It may difficult for some readers to follow the authors main story.

With the changes introduced, we hope the writing follows a more logical sequential flow.

• Clearly define the main objective and exploratory objectives, as the way they are written now, they are given equal emphasis which can be a bit confusing.

We improved the section where we explain our objective.

SECTION SPECIFIC COMMENTS

Title: proposed to maintain community healthcare workers rather than lay health workers. The lay health workers have not referred anywhere else in the manuscript.

Agreed -- we have updated the title.

ABSTRACT:

Line 27-28: "Mozambique has one of the highest rates of both TB and HIV in the world 28 but an estimated TB treatment coverage of only 57% in 2018". Needs clarity of the whether talking about incidence or mortality? Also consider rephrasing the sentence.

It refers to the incidence rates. We improved the sentence where this issue is described.

Line 39: The CHW screening activities yielded 1,502 notified and treated TB cases. The increase in the TB patients notified is only 763, please clarify why the different numbers?

The difference and relationship between yield (cases identified by the CHW) and increase in notification is fully explained in the analysis section. We cannot provide a detailed explanation but have tried to succinctly explain this it in the updated abstract.

Line 39-40: as we are looking for additionality of the intervention as compared to before the intervention, the correct number should be 763 and should be written and then the percentage.

You are right. Both the absolute number and the percentage are now in the abstract.

Line 39-40: the 1,502 is this number compared to baseline, or this is the number of TB cases contributed by CHW during the intervention period. This has to be clear.

1,502 is the number of patients identified by the CHW (yield) and it contributes to the notification increase of 763. Not all the 1,502 patients yielded will show as a notification increase because some of them would have found their way to diagnosis and treatment even in absence of the project. We hope that with the changes in the manuscript that is clarified in the methodology and analysis sections. We cannot provide the full explanation in the abstract but we do in the body of the manuscript.

INTRODUCTION

General comment

• There is no flow as there is no connection between sentences/there is a no story line for the reader to follow what the authors want to communicate.

We hope that with the changes in the manuscript that makes it easier and clearer to follow for readers.

• I think the references are before the full stop and not after. Please review the manuscript and change accordingly.

Looking at other PLOS One references it appears that the references are generally after the full stop or period.

• The article talks about the effect of CHW in increasing TB case finding, not even a single literature that highlight the effect of CHW in overall case finding is other areas with similar TB epidemiological profile.

We refer to work in other settings with similar aims in the discussion, and have added a number of citations.

• I seem to miss the primary objective of the study

We improved the explanation of our hypothesis and aims in the Introduction section.

Line 52: put the abbreviation of TB here and not in line 54. It makes sense to put the abbreviation in the first use of the word in question.

Thank you. We followed your recommendation.

Line 55: the authors are already talking about Mozambique; it is kind of a repetition to again mention Mozambique. Also, consider rewriting this sentence... "resulting in 162,000 new cases each year". Authors can consider to rewrite the sentence into something like "...translating to an estimated 162,000 new TB patients".

Thank you. We agree and abide to your recommendation.

Line 56-58: "This has been largely fueled by the HIV epidemic with a national 57 prevalence of 13.2%, but compounded by deep poverty with an estimated average 58 gross national income per capita of only \$440 USD". Please rewrite this sentence. Keep it simple, and separate each part and explain it clearly. This has been largely, what exactly? Consider starting a sentence like, TB is largely fueled by high HIV epidemic of 13.2%, poverty ......" Also, the word deep poverty has not objective measurement to a reader, it is just open to too much interpretations which are not standard.

We rewrote the sentence leaving it as free as possible of ambiguous wording.

Line 58-60: "Of the estimated incident TB 59 cases, 92,381 were diagnosed and notified in 2018 resulting in a treatment coverage 60 rate of only 57%". The sentence should go after end of Line 56 which talks about WHO estimated TB incidence rate. This is a logical flow when authors want to talk about treatment coverage.

We changed the sentence order and it makes it easier to follow for readers.

Line 68-73: authors to consider making this the last paragraph of your introduction section.

Thank you for the suggestion. We made the change.

Line 74-85: these are just too many hypotheses which seem not be related to the CHW role. I am curious to how you managed to test all these hypotheses. Also, the hypothesis lacks direction in terms whether increasing or decreasing your outcomes of interest.

We rephrased our hypothesis and tried to justify why these were related with our aim that CHW could improve TB notification.

METHODS

• Define the content of training package to CHW which includes the topics covered, for how many days and conducted by who. Was there any proficiency testing done to ensure the understanding of the CHW?

Please see response to reviewer \#1 who had a similar question. There were a variety of in person and peer assessments to document the adequate understanding of the CHW.

• The paragraphs have mixed information on study setting, population, data collection and study procedures. The authors can consider separating these into clear headings for easy of the readers to understand.

We tried to simplify the writing of the methodology and hope is now clearer.

Ethics statement

Ethics statement was only waived from University of Washington IRB. What about local or national ethics bodies in Mozambique? Was there no waiver applied to these ethics bodies as the research was done there?

We have updated the text to note that IRB was waived by University of Washington and the Mozambican IRB. Thank you noting this discrepancy.

Study setting

Study population and study definitions

Laboratory investigation

Need to mention the laboratory procedures used to confirm for TB.

Laboratory tests to confirm bacteriologically TB were either smear microscopy or Xpert MTB/RIF, depending on local availability. We introduced a sentence in the text explaining this protocol.

Statistical analysis

I am missing the statistical analysis of the effect of interventions within the clusters and comparison between intervention and control areas.

We clarified the analysis description in the methodology section. We are hoping it is now clearer, including the introduction of self-explanatory result tables in the results section.

Line 128: the bracket is out of place.

(We could not identify any bracket in line 128. However, we reviewed the text and ensured all brackets were in their place and any redundant bracket was erased).

RESULTS

General comments of results section

• Need consistency of reporting if putting numbers and proportions for each sub-population accessing a certain service.

• Intervention and control areas: consider additional tables (supplement) to describe the baseline characteristics of the intervention and control areas. You may include notification, population size and availability of diagnostic services (smear microscopy and Xpert).

• Table 1: is a bit difficult to read and make out the numbers and proportions. The table has been copied from excel and pasted here, I would suggest you have a Microsoft word table. The absolute numbers and proportions are separate, making the reading of this table difficult.

We have attempted to address these issues -- thank you.

Line 137-143: consider having a flow diagram for the readers to understand the table.

We improved table 1 that describes the logical flow of events. The original table is included as a sheet in the attached excel as an annex and may be easier to review than the image file in the word document.

Line 137: consider revising the text to "... CHWs identified 8532 presumptive TB patients...."

Thanks. We did it.

Line 138: consider adding proportion of the presumptive TB patients sent for laboratory testing

That was 93%. We included the proportion in the text.

Line 140: what do you mean valid sputum smear microscopy or Xpert MTB/RIF test? So, 16% of the tests had invalid results or they had negative results?

No, it means that 16% either they never provided a sample for testing (7%) or provided a sample but the result was invalid (9%) because of sample quality, test failure or other problems. We try to clarify it in the manuscript.

Line 140: "... 1508 (18%) of the ..." are these a sub-population of presumptive TB patients either tested for TB for of all presumptive TB patients? Consider to be specific of denominators when presenting the results of TB care cascade.

We ensured the denominators are well described in the text.

Line 143: "Using the TB REACH terminology..." is not just the additional TB patients from the intervention? Is it really a TB REACH terminology? Or is it necessary to mention that? The TB community would understand yield or additional TB patients.

You are right "TB REACH terminology" does not add any value. We rephrase the sentence. Thank you.

Line 144: the 1,508 all forms of TB notified from the intervention group, is different from line 39 in the abstract section which is 1,502 TB notified of all forms.

We corrected it. 1,508 is diagnosed, 1502 is corrected and enrolled into treatment.

Line 145: ".. and 286 contacts of TB were notified .." I think the use of the word notified for contacts is not appropriate. I would reserve for TB patients. authors can consider using the words like reported, identified etc.

Thank you. In addition, there was a typo. It was 826, not 286. We correct it.

Line 178: there is mention of regression analysis which is not mentioned in the statistical analysis under methods.

We rewrote the section to explain better our analysis. Hope it clarifies.

Line 148-154: these are the findings from the implementation period and lacks any comparison either from the control, or the intervention period? We need some sort of baseline data to compare the effect of CHW on PTLTFU and LTFU. What were your hypothesis in terms of direction on these outcomes?

We introduced an improved results description with 2 tables allowing comparisons between control and intervention districts and between historical baseline and implementation. Unfortunately, we could not have a baseline to compare the case recovery of PTLTFUs and LTFUs in this area -- this data is not routinely collected by the NTP.

DISCUSSION

• The discussion section was expected to comment on the decreased TB notification from control districts. Why is that? What is common among the control districts that affected case finding during the project period?

We have introduced our explanation of the reductions in the comparison districts.

• Were there any concurrent interventions that were implemented during the implementation of The TB REACH project in the intervention districts?

No. Our was the only active case finding intervention in the area. We clarified it in the methodology section.

• Are the results consistent with other CHW efforts in other settings with similar background epidemiological profile? There are many research outputs from many settings that will better inform the performance of this Mozambique experience, but those references are missing in this paper.

We make some references to similar interventions in other settings, see reference in the discussion section. These results are similar to CHW case-finding efforts in other settings but these are challenging to compare given the different local contexts, scale, and differences in the interventions.

• Line 266-268: reading from methods and part of the methods section, I had the impression that all presumptive TB patients were registered in the CHW registers based on the interventions done by CHW. So why the authors would not be able to fully analyze these different interventions? Authors need to clarify.

That is now clarified in the text. CHW registers only recorded presumptive patients in active case finding within the facilities and their cascade of care till diagnose and treatment. That is analyzed and presented. For the other activities, contact tracing was reported but not how many contacts were eventually considered active TB patients, although these were reported as such in the official system. As far as LTFU recoveries their activities prevented losses to follow up, as shown in Table 1, but were not directly contributing to newly notified cases.

• I am not sure of the role of JHPIEGO and CTB in this project. Line 229-239 is more of lessons learnt and its impact in Mozambique in developing CHW TB guidelines. Authors need to consider to shorten this section, and if need be present this additional information in the supplement text.

We included this description to put our work in perspective of the changes taking place in Mozambique. We tried, however, to shorten the section.

JHPIEGO, write in long form.

JHPIEGO now claims to be named by this name instead of the old "Johns Hopkins Program for International Education in Gynaecology and Obstetrics". We introduced, however, a note making clear it is an international NGO.

• Line 240-262: part of the discussion on the yield should go to the first two paragraphs and discuss more the results and compare with other settings.

You are right. That seems more logical and we changed the order.

REFERENCES

General remarks

• The name of organization or institutions should be written in full, and they are not shorted as individual names. Please check the following:

• Online reference can be made on the web references only? Please check all the references and see if they fit the journal guidelines.

We checked and corrected where appropriate. Thanks.

Check reference no. 4. What is "Bank W"?

That was supposed to mean The World Bank. We corrected it.

Check reference no. 15. What is "Partnership. ST"?

That was supposed to mean Stop TB Partnership. We corrected it.
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